“Hey model, if I prompt you with the marker genes for a cell type, can you complete the transcription factors that you believe would be highly expressed with expression of these genes?” posed ...
CEO David Barrett, JD, noted there has been “a nice uptick” in Q1 in start-up funding compared to the same quarter last year, ...
The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
The data shows that immune cells converge at sites of motor neuron loss and TDP-43 pathology with distinct patterns depending on the ALS type.
The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...
When these anchors are attached to cancer drugs, they attach to cell membranes and shrink tumors better than unmodified drug ...
These “living therapeutics” can sustain themselves in vivo and survive in biological environments including tumors, inflamed ...
A study in mice showed how T2D drug metformin exerts multiple clinical effects through selective inhibition of mitochondrial ...
Sickle cell warrior Victoria Gray, the first patient to enroll in the Casgevy gene editing trial, shared some highs and lows ...
One of the winners of the 2026 ASGCT Catalyst Award, Kiran Musunuru, MD, PhD, delivered a sobering lecture on the legacy of ...
A Phase I/II clinical trial shows that a stem cell transplant that removes CD33 from donor cells using CRISPR can prevent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results